Tirzepatide for Night Eating Syndrome (NES) and Sleep-Related Eating Disorder (SRED): a presentation of two cases

Tirzepatide is a glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) analog approved for treatment of Type 2 Diabetes Mellitus, obesity and moderate-to-severe obstructive sleep apnea in patients with obesity. The role of the GLP-1 drugs in treating eating disorders is unclear. Night Eating Syndrome (NES) and Sleep-Related Eating Disorder (SRED) are conditions in which sleep parasomnias and eating behaviors overlap. Their treatment remains challenging and includes cognitive behavioral therapy and pharmacotherapy using topiramate, selective serotonin reuptake inhibitors, or anorectic serotonergic medications. We report two cases of NES, one of them with comorbid SRED, treated successfully with tirzepatide.